NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SINGAPORE, SOUTH AFRICA OR NEW ZEALAND OR IN ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL. The prospectus relating to Active Biotech's rights issue has now been published and is available on the company's website, www.activebiotech.com. The prospectus can also be ordered from Active Biotech by telephone +46 (0)46 19 20 00. For further information, please contact: Tomas Leanderson, CEO Tel: +46 (0)46 19 20 95 E-mail: tomas.leanderson@activebiotech.com Hans Kolam, CFO Tel: +46 (0)46 19 20 44 E-mail: hans.kolam@activebiotech.com Active Biotech AB (publ) (Nasdaq Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, and tasquinimod, an oral immunomodulatory, anti-metastatic substance for the treatment of prostate cancer. The objective of the preclinical ISI project is to produce new, patentable chemical compounds for treatment of diseases in the company's focus areas. Please visit www.activebiotech.com for more information. Active Biotech is required to publish the information contained in this press release in accordance with the Swedish Securities Market Act. This information was provided to the media for publication at 8:30 am CET on December 5, 2014. Important information This press release is not an offer to subscribe for shares in Active Biotech investors should not subscribe for or purchase any securities, except on the basis of information provided in the prospectus. This press release may not be made public, released or distributed, directly or indirectly, in or into the United States, Australia, Hong Kong, Japan, Canada, Singapore, South Africa or New Zealand or in any other jurisdiction in which the distribution of this press release would be unlawful. Further, this press release does not constitute an offer to sell new shares, paid subscribed for shares ("BTA") or subscription rights to any person in any jurisdiction in which it is unlawful to make such offer to such person or where such action would require additional prospectuses, registration or other measures other than those pursuant to Swedish law. The prospectus, application form and other documents associated with the rights issue may not be distributed in or to any country where such distribution or the rights issue would require such measures set forth in the preceding sentence or be in violation of the regulations of such country. The new shares, BTAs and subscription rights have not been recommended by a United States federal or state securities commission or regulatory authority. No new shares, BTAs, subscription rights or other securities issued by Active Biotech have been or will be registered under the U.S. Securities Act of 1933, or under the securities legislation in any state of the United States or any province in Canada. Accordingly, no new shares, BTAs, subscription rights or other securities issued by Active Biotech may be transferred or offered for sale in the United States or Canada, other than in such exceptional cases that do not require registration. The securities issued in the rights issue will not be offered to the public in the United States. Active Biotech has not authorized any offer of securities to the public in any country in the European Economic Area ("EEA") other than Sweden. In other member states in the EEA which have implemented the Directive 2003/71/EC (the "Prospectus Directive") (each, a "Relevant Member State"), no action has been undertaken and will not be undertaken to make an offer of securities to the public requiring publication of a prospectus in any Relevant Member State. As a result, the securities may only be offered in Relevant Member States to (a) any legal entity which is a qualified investor as defined in the Prospectus Directive; or (b) any person falling within Article 3(2) of the Prospectus Directive. The rights issue is only directed at (i) persons who are outside the United Kingdom or (ii) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") and (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2) of the Order (all such persons together being referred to as "relevant persons"). The securities issued in the rights issue will only be available to and will only be engaged with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents. [HUG#1877618]
Prospectus relating to Active Biotech's rights issue
Top 10 Most Recent News Articles
Dawson Struggles With Q3 Losses Despite Growth Prospects
Profit and loss dance around like a jittery stock, and Dawson Geophysical is feeling the heat this third quarter. Numbers are in, and we’re seeing a net loss of $5.2 million, translating to $0.17 per share—ouch. Not to mention a negative Adjusted EBITDA of $2 million. Compared to last year's hopes, that's a serious belly flop. Revenue Down, Hopes Up In a fetching...
Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026
A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...
Continue Reading
Nevada Expands Rural Youth Mental Health Access
Nevada's Rural Mental Health Crisis When you're navigating the barren stretches of rural Nevada, the scenic views can be breathtaking. But for many families, finding basic services like mental health care is as challenging as striking water in the desert. Cartwheel Care has taken the bull by the horns with their latest initiative to bridge this glaring gap. Partnering...
Continue Reading
Lululemon Faces Class Action over Alleged Missteps
Trouble Brewing for Lululemon Y'ever get that gut feeling when something doesn't smell right? Well, Lululemon Athletica (NASDAQ: LULU) investors are probably feeling that now. A class action's kicking up dust over what some are saying was a downright bumpy ride. The brainiacs at Robbins LLP urge those who've lost bucks riding the LULU train to step forward ahead of the...
Continue Reading
MoneyGram and Solflare Boost Crypto Cash-Out Options
Crypto Meets Cash: A New Partnership in Money Movement Here's something to chew over your morning joe: MoneyGram's stepping up its game in the crypto world. They're pairing up with Solflare to let folks convert their USDC into hard cash across 170 countries and territories—no fees until New Year's Eve. It's like crypto's getting a passport to the physical world and not...
Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win
Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...
Continue Reading
FDA Changes Shake Up Medtech Inspections Landscape
Inspecting the Changing FDA Landscape If you’ve been treating FDA inspections like a ride down memory lane, it's time for a wake-up call. What F. David Rothkopf plans to tell the medical device teams at the MEDevice Silicon Valley event is simple: the game has changed. The FDA’s Quality Management System Regulation (QMSR) that kicked in on February 2, 2026, isn’t...
Continue Reading
BETR's Legal Tangle: A Deeper Dive into Investor Turmoil
BETR's Shaky Ground: When Promises Fall Short In the rough-and-tumble world of finance, there's little room for empty promises. Better Home & Finance Holding Company (NASDAQ: BETR) might have to learn that the hard way. Investors who snagged shares between March 13 and August 6, 2026, are now clutching their heads as they watch their investments nosedive. When companies...
Continue Reading
Carolina Pines Tackles Rural Healthcare Myths on TV
Rural Healthcare Battles the Big City Myth Picture this: you're in a tiny town where everyone knows your dog's name, but some think you've got to head to the city for top-notch medical care. That's where Carolina Pines Regional Medical Center steps in. They’ve snagged a spot on 'All Access with Andy Garcia', shining a light on how investments in tech and talent keep...
Continue Reading
Roche Delivers Endotrophin Assay to Nordic Bioscience Lab
Roche Opens New Frontier in Diagnostic Biomarkers Get ready to chew on this: Roche Diagnostics is bringing something new to Nordic Bioscience's CLIA lab. They're offering up their Endotrophin research prototype assay on the cobas® e801 Analyzer. Now, what does this mean for the scientific world? Well, it might just shake things up for those battling cardiovascular and...
Continue ReadingTop 5 Most Recently Viewed Articles
Investors Eye Holiday Spending Surge with Retail ETFs
Holiday Spending Trends Point to Retail ETF Gains As the festive season kicks off, investors are buzzing with anticipation. The projections indicate a remarkable surge in U.S. holiday sales, expected to hit between $1.01 trillion and $1.02 trillion. This optimism is driven by strong consumer demand, early sales promotions, and a decrease in inflation, setting a promising...
Continue Reading
Titan Mining Announces Details for Upcoming AGM Meeting
Titan Mining Corporation's Upcoming Annual General Meeting Titan Mining Corporation (TSX: TI; OTCQB: TIMCF) is set to hold its annual general meeting soon, a much-anticipated event for shareholders and stakeholders alike. The date is indeed significant as it marks an opportunity for the company to engage directly with its investors. Meeting Details and Importance The...
Continue Reading
She Said Yes Launches Eco-Friendly Jewelry Initiative
She Said Yes Empowers Customers with Tree-Planting Initiative She Said Yes, a renowned jewelry brand dedicated to using conflict-free diamonds and recycled gold, has unveiled an exciting partnership with WeForest to create a meaningful environmental initiative. This new program enables every jewelry purchase to contribute directly to global reforestation efforts,...
Continue Reading
Whale Traders Target Trump Media's Future with Options Movements
Whale Traders Target Trump Media's Future with Options Movements Recently, investors with substantial capital have been showing strong interest in Trump Media & Technology (NASDAQ: DJT). This surge in activity is a signal that retail traders should pay attention to. Today, unusual trading patterns have been detected, hinting that significant financial players are...
Continue Reading
Partnership Boosts Digital Transformation in Japan's Life Sciences
Transforming the Life Sciences Industry through Digital Solutions ValGenesis Inc. has teamed up with Hitachi Industry & Control Solutions, Ltd. to spearhead a transformative initiative aimed at elevating the capabilities of life sciences companies in Japan. This innovative partnership intends to bring forth cutting-edge digital validation solutions to streamline processes...
Continue Reading